ETBX-071

· ImmunityBio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ETBX-071, covering 2025-05-06 to 2025-05-06. Get the full timeline:

Most recent: Clinical Trial Update: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. [Phase 2]

See pricing